This is a virtual panel discussion about whether biosimilars—cheaper copies of expensive biologic drugs—have finally gained enough market traction to meaningfully lower drug costs. The speakers explore what's working, what's broken in the system, and what comes next as more blockbuster drugs face biosimilar competition.

• The first wave of biosimilars has launched, with more major drugs facing lower-cost competition soon
• The FDA has been removing regulatory barriers to speed biosimilar approvals in an effort to reduce drug spending
• Policy shifts and structural problems in the healthcare system could derail the cost-savings momentum biosimilars have built

The Department of Labor’s proposal would force pharmacy benefit managers to disclose drug pricing details to employers and open their books to audits. More than 500 comment letters show PBMs and insurers fighting the rule, while some employers and startups back it and drugmakers offer mixed support.

• DOL's proposed rule would force PBMs to disclose rebates, fees, and spread pricing to employers and submit to audits
• Over 500 comment letters split along predictable lines: PBMs/insurers oppose it as exposing confidential contracts, while Cost Plus Pharmacy and business groups support it as curbing hidden markups
• Drugmakers back reining in PBMs generally but want the disclosure rules narrowed to administrative fees, excluding drug-specific rebate data that competitors could exploit
• Rule could shift negotiating power from PBMs to employers, though employers would then face more complex data to manage in contract talks

Mark Cuban discusses his approach to fixing healthcare, emphasizing transparency in drug pricing and the need to dismantle the influence of pharmacy benefit managers. He advocates for cash pricing legislation and supports the Break Up Big Medicine Act to separate insurance companies from their non-insurance interests.

• The Dallas Mavericks paid $169,000 for generic drugs that would have cost just $19,000 through Cuban's Cost Plus company.
• Cuban backs the Break Up Big Medicine Act, which would force insurance companies to divest their PBM arms.
• He wants legislation requiring cash drug payments to count toward insurance deductibles, plus state-controlled formularies to curb PBM power.
• He gave TrumpRx an "A-" and says FDA application costs, not tariffs, are the real barrier to bringing generic manufacturing to the US.

Mark Cuban and Optum CEO Patrick Conway engaged in a heated discussion about drug prices and pharmacy benefit managers, highlighting their differing views on how to reform the healthcare system. Cuban argued for breaking up large insurance companies and criticized the lack of transparency in PBM contracts, while Conway emphasized the need to tackle high hospital and pharmaceutical costs. Both acknowledged the other's contributions but remained divided on the root causes of high drug prices and solutions.

• Cuban challenged Conway to name a specific Optum customer he could call to verify claims about PBM contract transparency
• Cuban advocates breaking up large insurance companies as a fix, blaming opaque PBM contracts for inflated drug prices
• Conway countered that high hospital and pharmaceutical costs, not just PBMs, are the core drivers of the problem
• Despite the confrontational exchange, both men acknowledged each other's contributions while disagreeing on root causes and solutions